September 9, 2021 News by Steve Bryson, PhD ADS-5102 Aided Walking Speed in Select MS Patients in INROADS Trial An extended-release formulation of amantadine, ADS-5102 was significantly more effective than a placebo at increasing walking speed in multiple sclerosis (MS) patients who had difficulty with this, particularly younger patients with a shorter disease course, the INROADS Phase 3 trial demonstrated. Further clinical work on this investigative…
June 29, 2020 Columns by Ed Tobias MS News That Caught My Eye Last Week: Mayzent, Hookworm Therapy, Walking and Falling, ADS-5102 NICE Does Not Favor Adding Mayzent to NHS England for Active SPMS Currently, the only disease-modifying therapy approved for use in the National Health Service is Betaferon (interferon beta-1b). That’s a 20-year-old treatment considered to be one of the least effective of the DMTs. NICE concedes that clinical trials…
June 23, 2020 News by Joana Carvalho, PhD Adamas Stopping Further Work on ADS-5102 for Walking Problems in MS Adamas PharmaceuticalsĀ has decided to stop further clinical development of ADS-5102 (amantadine), intended to help people with multiple sclerosis (MS) who have difficulties with walking. The decision came after the company reviewed findings from a comprehensive analysis of…
May 9, 2019 News by Joana Carvalho, PhD #AANAM ā Adamas Provides Update on Phase 3 INROADS Trial Testing ADS-5102 for MS Adamas Pharmaceuticals announced the study design and baseline characteristics of patients enrolling in the company’s ongoing Phase 3 trialĀ testing the efficacy and safety of ADS-5102 (amantadine) extended-release capsules in patients with multiple sclerosis (MS) who have difficulty walking. The data were presented in a poster,…
March 25, 2019 Columns by Ed Tobias MS News that Caught My Eye Last Week: Walking Med Trial Recruiting, DMT Risk Tolerance, Sex and MS Phase 3 Trial of ADS-5102 Recruiting Participants of All MS Types This medication is similar to Ampyra (dalfampridine) because its goal is to improve walking in those with MS. It sure would be nice if we had another medication approved that could do that. Though this trial began recruiting…
March 22, 2019 News by Jose Marques Lopes, PhD Phase 3 Trial of ADS-5102 Recruiting Participants of All MS Types A Phase 3 trial testing ADS-5102 (amantadine) extended release capsules in all types of multiple sclerosis (MS) is enrolling participants to determine whether the oral therapy can improve walking speed. A total of 570 adults with MS, ages 18 to 70 years, who have difficulty walking will be…
April 5, 2018 News by Jose Marques Lopes, PhD 1st Patient Enrolls in Phase 3 Trial of ADS-5102 as Way of Improving Walking Ability, Adamas Announces A Phase 3 trial testing an oral once-a-day therapy ā ADS-5102 (amantadine) extended release capsules ā inĀ multiple sclerosis (MS) patients with walking difficulties has enrolled its first participant, Adamas Pharmaceuticals announced. The multi-center, double-blind study (NCT03436199) will assess ADS-5102 in about 570 such patients at five sites…
February 7, 2018 News by Patricia Inacio, PhD Adamas Therapy Improves Multiple Sclerosis Patients’ Walking Speed, Trial Shows The walking speed of multiple sclerosis patients taking Adamas Pharmaceuticals’Ā ADS-5102 (amantadine) increased by 16.6 percent more those taking a placebo, a Phase 2 clinical trial reports. Another finding was that more of the treated patients increased theirĀ walking speed by 20 percent or more during the four-week trial. The study,…
February 21, 2017 News by Patricia Silva, PhD #ACTRIMS2017 – Phase 2 Trial Data Shows Better Walking Speeds in MS Patients Using ADS-5102 Results from aĀ Phase 2 proof-of-concept studyĀ ofĀ ADS-5102Ā (amantadineĀ HCl), showing that multiple sclerosis patients givenĀ the extended-release oral treatment improved their walking speed, will be presentedĀ at ACTRIMS 2017Ā this week. Findings in theĀ poster, āA Phase 2 Study of ADS-5102 (amantadine hydrochloride) Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment,ā…
June 17, 2016 News by Patricia Silva, PhD Adamas Reports Positive Results in Study of Drug to Treat MS Patients with Walking Difficulties Adamas Pharmaceuticals recently reported positive results from its Phase 2 proof-of-concept clinical trial evaluating ADS-5102 (amantadine HCl), an extended-release version of amantadine, inĀ multiple sclerosis (MS) patients with difficulties inĀ walking. The trial (NCT02471222),Ā aĀ double-blind, placebo-controlled and two-arm parallel groupĀ study,Ā evaluated ADS-5102 given once dailyĀ at 340 mg, at bedtime, for four…
October 15, 2015 News by Patricia Silva, PhD Adamas Reports Walking Improvement in MS Models with ADS-5102 (Amantadine HCl) Adamas Pharmaceuticals, Inc., a pharmaceutical company focused on chronic conditions that affect the central nervous system, recently announced results from two non-clinical studies showing that the companyās product candidate ADS-5102 can be potentially applied as a treatment for multiple sclerosis (MS) symptoms. MS is a chronic, progressive neurodegenerative autoimmune…
June 12, 2015 News by Patricia Silva, PhD Adamas Begins Phase 2 Multiple Sclerosis Study for Patients with Walking Impairment Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapies forĀ chronic disorders of the central nervous system, recently announced the beginning of a Phase 2 study that willĀ assess the efficacy of amantadine HCl (ADS-5102) in patients with a diagnosis of multiple sclerosis (MS) who suffer from walking impairments. “We are…